Continuing the Conversation: Optimizing Frontline Immunotherapy Outcomes in NSCLC and Managed Care Considerations

Continuing the Conversation: Optimizing Frontline Immunotherapy Outcomes in NSCLC and Managed Care Considerations is organized by Pharmacy Times Continuing Education (PTCE).,Release date: July 29, 2022,Expiration date: July 29, 2023,Description:,When involved in the treatment and management of patients with non-small cell lung cancer (NSCLC), managed care pharmacists must consider how the use of predictive biomarkers can affect patient response to therapy. Several organizations recommend the use of biomarker testing before initiating treatment for patients with NSCLC, and managed care professionals can ensure these recommendations are incorporated into treatment protocols. Evidence for first-line treatment regimens with immune checkpoint inhibitors (ICIs) will be presented, as well as considerations for managing immune-mediated adverse effects of therapy. This activity will also explore strategies managed care pharmacists can take to minimize the financial burden associated with the use of ICIs in patients with NSCLC.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Review the efficacy and safety of emerging frontline immune checkpoint inhibitors (ICIs) used as monotherapy and in combination regimens,• Indicate the impact of ICIs and programmed death-ligand 1 testing on cost-effectiveness and patient-reported outcomes related with frontline use of ICIs in advanced non-small cell lung cancer